388 related articles for article (PubMed ID: 28178630)
21. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.
Prichard CN; Kim S; Yazici YD; Doan DD; Jasser SA; Mandal M; Myers JN
Laryngoscope; 2007 Apr; 117(4):674-9. PubMed ID: 17429874
[TBL] [Abstract][Full Text] [Related]
22. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
24. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer.
Marano F; Argenziano M; Frairia R; Adamini A; Bosco O; Rinella L; Fortunati N; Cavalli R; Catalano MG
Thyroid; 2016 May; 26(5):705-16. PubMed ID: 26906083
[TBL] [Abstract][Full Text] [Related]
26. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
27. miR-381-3p attenuates doxorubicin resistance in human anaplastic thyroid carcinoma via targeting homeobox A9.
Zhang Y; Li K; Wang W; Han J
Int J Exp Pathol; 2021 Aug; 102(4-5):209-217. PubMed ID: 34719830
[TBL] [Abstract][Full Text] [Related]
28. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
29. Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities.
Gaikwad S; Chakraborty A; Salwe S; Patel V; Kulkarni S; Banerjee S
J Biochem Mol Toxicol; 2018 Sep; 32(9):e22176. PubMed ID: 29992683
[TBL] [Abstract][Full Text] [Related]
30. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
31. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
[TBL] [Abstract][Full Text] [Related]
32. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation.
Chang JW; Kang SU; Choi JW; Shin YS; Baek SJ; Lee SH; Kim CH
Free Radic Biol Med; 2014 Feb; 67():115-30. PubMed ID: 24216474
[TBL] [Abstract][Full Text] [Related]
33. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
Pan Y; Liu P; Chen D; Dou L
Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
[TBL] [Abstract][Full Text] [Related]
34. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Chen G; Xu S; Renko K; Derwahl M
J Clin Endocrinol Metab; 2012 Apr; 97(4):E510-20. PubMed ID: 22278418
[TBL] [Abstract][Full Text] [Related]
35. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.
D'Agostino M; Voce P; Celano M; Sponziello M; Moretti S; Maggisano V; Verrienti A; Durante C; Filetti S; Puxeddu E; Russo D
Thyroid; 2012 Feb; 22(2):138-44. PubMed ID: 22191389
[TBL] [Abstract][Full Text] [Related]
36. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer.
Jin Z; Cheng X; Feng H; Kuang J; Yang W; Peng C; Shen B; Qiu W
Cell Physiol Biochem; 2017; 44(4):1471-1484. PubMed ID: 29190616
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
[TBL] [Abstract][Full Text] [Related]
38. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway.
Wang XM; Liu Y; Fan YX; Liu Z; Yuan QL; Jia M; Geng ZS; Gu L; Lu XB
Cancer Biol Ther; 2018 Jul; 19(7):590-597. PubMed ID: 29561707
[TBL] [Abstract][Full Text] [Related]
39. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells.
Kim E; Matsuse M; Saenko V; Suzuki K; Ohtsuru A; Mitsutake N; Yamashita S
Thyroid; 2012 Jul; 22(7):717-24. PubMed ID: 22650230
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.
Ma L; Cheng Q
Biochem Biophys Res Commun; 2018 Apr; 498(4):912-917. PubMed ID: 29534964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
